- CA$1.15bn
- CA$1.06bn
- CA$450.09m
Brief: Knight Therapeutics Submits Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Mexico
Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Crexont® (Carbidopa And Levodopa) Extended-Release Capsules In Canada
Brief: Knight Therapeutics And Sumitomo Pharma Enter Into Exclusive Licensing Agreements To Commercialize Sumitomo’S Canadian Portfolio
Brief: Knight Therapeutics Announces Relaunch Of Onicit® In Brazil And Mexico
Brief: Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
Canada Research Roundup: Canadian Pacific Kansas City , Doman Building Materials Group, MAG Silver
Canada Research Roundup: Cameco, Labrador Iron Ore Royalty, Nexgen Energy
Press Digest: Canada - March 12
Brief: Knight Therapeutics Inc: Entered In Definitive Asset Purchase Agreement With Endo & Paladin Pharma To Acquire Paladin Business
Brief: Knight Therapeutics Announces Filing Of New Drug Submission For Qelbree (Viloxazine) In Canada
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Mexico
Canada Research Roundup: Barrick Gold, MAG Silver, TFI International
Brief: Knight Announces Normal Course Issuer Bid
Brief: Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
Brief: Knight Therapeutics Announces Launch Of Minjuvi In Brazil
Brief: Knight Therapeutics Announces Regulatory Submission Of Fostamatinib In Brazil
Brief: Knight Therapeutics Enters Into Exclusive License Agreement With Supernus Pharmaceuticals For Qelbree® (Viloxazine) In Canada
Brief: Knight Therapeutics Announces CMED Price Approval Of Minjuvi In Brazil
Brief: Knight Therapeutics Announces Regulatory Submission Of Pemigatinib In Brazil